Compare ACDC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | EVO |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.3M | 821.2M |
| IPO Year | 2021 | N/A |
| Metric | ACDC | EVO |
|---|---|---|
| Price | $6.46 | $2.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.83 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.4M | 108.5K |
| Earning Date | 03-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,941,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.37 | $7.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $2.31 |
| 52 Week High | $10.70 | $4.80 |
| Indicator | ACDC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 28.78 |
| Support Level | $3.48 | $2.31 |
| Resistance Level | $7.47 | $3.78 |
| Average True Range (ATR) | 0.49 | 0.09 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 56.05 | 9.98 |
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.